Clinical trials: Rheumatoid Arthritis (RA)
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically…
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
- Trial name
- NCT06991114
- Testing
- Allogeneic NK Cells
- Where
- 52 sites in United States, Brazil and 9 more
- Volunteers
- 90 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Rheumatoid Arthritis
A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis
The primary purpose of the study is to evaluate the effect of ASP1707 twice daily on the pharmacokinetics of once weekly oral methotrexate (MTX).
- Trial name
- NCT02867306
- Testing
- ASP1707, methotrexate (MTX)
- Where
- Moldova
- Volunteers
- 10 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Arthritis, Rheumatoid
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab
This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable…
- Trial name
- NCT02792699
- Testing
- ABP 798, Rituximab (US), Rituximab (EU)
- Where
- 55 sites in United States, Bulgaria and 4 more
- Volunteers
- 311 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
Long-term extension of a multi-site, first-in-human study to assess safety and efficacy of an active implantable Vagus Nerve Stimulation (VNS) device in adult patients with active moderate-to-severe rheumatoid arthritis who have…
- Trial name
- NCT04862117
- Testing
- SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- SetPoint Medical Corporation
Rheumatoid Arthritis
The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience
Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require…
- Trial name
- NCT03109470
- Sponsor
- Pope Research Corporation
Rheumatoid Arthritis
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
This Phase 3, randomized, open-label, multicenter study in rheumatoid arthritis (RA) patients with low disease activity (Disease Activity Score 28 [DAS28] >2.8 and <3.5) is being conducted to evaluate induction of remission by…
- Trial name
- NCT00521924
- Testing
- infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate
The objective of this study is to evaluate the efficacy, pharmacokinetics, pharmacodynamics and safety of ASP1707 in combination with MTX in postmenopausal female patients with RA.
- Trial name
- NCT02884635
- Testing
- ASP1707, Methotrexate
- Where
- 27 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Astellas Pharma Inc
Arthritis, Rheumatoid
Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
Prospective, open-label, multicenter, dose escalation, safety with pharmacokinetics (PK) and dosimetry study of injected Tc 99m tilmanocept in the detection of and assessment of localization to skeletal joints in subjects with…
- Trial name
- NCT02865434
- Testing
- Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Rheumatoid Arthritis
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
To evaluate clinical efficacy and tolerability of MRA, patients with RA are randomized to receive either MRA or conventional DMARDs.
- Trial name
- NCT00144508
- Testing
- MRA (Tocilizumab), current treatment
- Volunteers
- 306 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients
The objective is to prove the equivalence in efficacy and safety of HD203 and Enbrel® in combination with Methotrexate in patients with rheumatoid arthritis.
- Trial name
- NCT01270997
- Testing
- Etanercept
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- Hanwha Chemical
Rheumatoid Arthritis
Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis
The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX
- Trial name
- NCT00233558
- Testing
- adalimumab (up to 9 months exposure), methotrexate
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Abbott
Rheumatoid Arthritis
An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally…
- Trial name
- UPDATE (NCT05327920)
- Where
- 8 sites in Hungary
- Volunteers
- 93 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy.
- Trial name
- IMAGE (NCT00299104)
- Testing
- folate, methotrexate, methylprednisolone
- Volunteers
- 755 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis
The purpose of this study is to assess whether DCE-MRI can detect changes of active disease in rheumatoid arthritis (RA) patients after 4, 8 and 12 weeks of etanercept.
- Trial name
- NCT00361634
- Testing
- Etanercept
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA)
Evaluation of Health Related Quality of Life (HRQL) is of a paramount importance in assessing the impact of rheumatoid arthritis on patients' health status, however when costs associated with rheumatoid arthritis are also taken…
- Trial name
- HEOR (NCT01078116)
- Where
- 10 sites in Greece
- Volunteers
- 124 people
- Sponsor
- Abbott
Rheumatoid Arthritis (RA)
Masitinib in Refractory Active Rheumatoid Arthritis
The objective is to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1.
- Trial name
- NCT01410695
- Testing
- masitinib 3 mg, masitinib 6.0 mg, methotrexate
- Where
- Czechia
- Volunteers
- 324 people
- Sponsor
- AB Science
Rheumatoid Arthritis
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate.
- Trial name
- FLEX M (NCT01198002)
- Testing
- LY2127399, Methotrexate
- Where
- 234 sites in United States, Argentina and 21 more
- Volunteers
- 1,041 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis (RA)
QLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis
The objective of this randomized, double-blind, placebo-controlled phase II clinical trial is to investigate the safety and efficacy of QLS12010 in subjects with moderate-to-severe rheumatoid arthritis.The main questions it aims…
- Trial name
- NCT07377773
- Testing
- QLS12010
- Volunteers
- 180 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Rheumatoid Arthritis (RA), Crohn's Disease (CD)
UCB Cimzia Pregnancy Follow-up Study
The purpose of this observational follow-up study is to collect data systematically on pregnancies and offspring of women who become pregnant while participating in a Certolizumab Pegol (CZP) study or whose pregnancies have…
- Conditions
- Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
- Trial name
- NCT02775656
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Rheumatoid Arthritis
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Primary Objective: To document the long-term safety of sarilumab added to non-methotrexate (non-MTX) disease-modifying antirheumatic drugs (DMARDs) or as monotherapy.
- Trial name
- NCT02373202
- Testing
- Sarilumab, Sulfasalazine, Leflunomide
- Where
- 40 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Sanofi